SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: rkrw who wrote (2802)7/12/2011 10:50:00 AM
From: IRWIN JAMES FRANKEL  Read Replies (1) | Respond to of 3027
 
>>to the unexpected discoveries of a positive MW-toxicity correlation and meaningful disease activity at lower MW.

That will be critical IMO. Was manipulation of the MW's effect on the SE profile foreseeable by skilled in the art? IF SO, then the finding is an unpatentable advance.

ij



To: rkrw who wrote (2802)7/27/2011 7:17:48 PM
From: DewDiligence_on_SI  Respond to of 3027
 
The analysts should have stayed at the trial longer than two days, according to MYL's CEO:

siliconinvestor.com